Inventiva S.A. (NASDAQ: IVA)
$2.6200
+0.2000 ( +8.26% ) 184.5K
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Market Data
Open
$2.6200
Previous close
$2.4200
Volume
184.5K
Market cap
$138.23M
Day range
$2.3100 - $2.7010
52 week range
$1.5300 - $4.7500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Form 6-K | 2 | May 30, 2024 |
6-k | Form 6-K | 2 | May 21, 2024 |
6-k | Form 6-K | 2 | May 16, 2024 |
6-k | Form 6-K | 2 | May 13, 2024 |
6-k | Form 6-K | 2 | May 13, 2024 |
20-f | Annual reports | 181 | Apr 03, 2024 |
6-k | Form 6-K | 2 | Mar 27, 2024 |
6-k | Form 6-K | 2 | Mar 18, 2024 |
6-k | Form 6-K | 2 | Mar 07, 2024 |
6-k | Form 6-K | 2 | Feb 15, 2024 |